Cytokinetics reported continued commercial momentum for MYQORZO, with approximately 1,500 patients dispensed the cardiovascular medicine by the end of the second quarter as the company expanded the product into additional international markets.
More than 700 unique healthcare providers had prescribed MYQORZO as of June 30, and over 80% of patients receiving therapy were on paid prescriptions. The company generated $25.3 million of MYQORZO net product revenue during Q2, consisting of $23 million in U.S. revenue and $2.3 million from initial distributor inventory purchases in Germany.
Cytokinetics launched MYQORZO in Germany in June and received marketing authorization in the United Kingdom for adults with symptomatic obstructive hypertrophic cardiomyopathy. NICE also recommended aficamten for use in England and Wales, while the Dutch Ministry of Health approved reimbursement effective August 1.
The company has submitted 10 Health Technology Assessment dossiers to support European market access and expects to launch MYQORZO in more than five additional markets by the first half of 2027. Applications have also been submitted in Hong Kong and Taiwan through Cytokinetics’ collaboration with Sanofi, while reviews are ongoing in Canada and Switzerland.
Another potential expansion opportunity is emerging from ACACIA-HCM, Cytokinetics’ pivotal Phase 3 trial evaluating aficamten in symptomatic non-obstructive hypertrophic cardiomyopathy. The study met both primary endpoints, showing statistically significant improvements in health status and maximal exercise performance. The company plans to submit a supplemental New Drug Application in the fourth quarter of 2026.
Cytokinetics ended June with approximately $1.7 billion in cash, cash equivalents and investments, compared with $1.1 billion at the end of March. During the quarter, it raised approximately $760.1 million in net proceeds through a public stock offering.
Total second-quarter revenue was $28.6 million, compared with $66.8 million a year earlier, when results included $64.4 million of license and milestone revenue. The company reported a quarterly net loss of $198.8 million.
KEY QUOTES:
“Our second quarter results demonstrate commercial launch momentum for MYQORZO alongside continued excellence for our development pipeline, both hallmarks of continued strong execution for our maturing business. In the U.S., we continued to build launch velocity evidenced by expanding physician adoption and increasing patient access. Internationally, we launched MYQORZO in Germany and laid the foundation for broadening access to aficamten by submitting reimbursement dossiers alongside regulatory filings advancing in multiple countries in Europe.”
“We look forward to sharing results from ACACIA-HCM later this month and submitting a supplemental NDA to the U.S. Food and Drug Administration in the fourth quarter. Having also secured additional capital during the recent quarter, we have the financial resources to invest in both the global commercialization of MYQORZO and the continued progression of our pipeline, positioning us well to maximize the potential of our specialty cardiology franchise.”
Robert I. Blum, President and CEO of Cytokinetics
